NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Dabigatran etexilate for the prevention of stroke or systemic embolism in atrial fibrillation.

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Boehringer-Ingelheim (dabigatran)	Board of Community Health Councils in Wales
Patient/carer groups	 British Cardiovascular Industry Association British National Formulary Commissioning Support Appraisals Service Department of Health, Social Services and Public Safety for Northern Ireland Medicines and Healthcare products Regulatory Agency National Association of Primary Care NHS Alliance NHS Confederation NHS Purchasing and Supply Agency
 Different Strokes Equalities National Council Heart Care Partnership (UK) HEART UK 	 NHS Quality Improvement Scotland Public Health Wales NHS Trust Scottish Medicines Consortium
 Muslim Council of Great Britain Muslim Health Network South Asian Health Foundation Specialised Healthcare Alliance Stroke Association 	 Possible comparator manufacturers Actavis UK (aspirin, warfarin) Alliance Pharmaceuticals (aspirin) Arrow Generics (aspirin, warfarin) Aspar Pharmaceuticals (aspirin) Bayer (aspirin)
 Professional groups Anticoagulation Specialist Association (ASA) British Association for Nursing in Cardiac Care British Association for Service to the Elderly British Association of Stroke Physicians 	 Bristol-Myers Squibb (aspirin) Dexcel-Pharma (aspirin) Focus Pharmaceuticals (aspirin) Galpharm International (aspirin) Generics UK (aspirin, warfarin) Genus Pharmaceuticals (aspirin) Goldshield Pharmaceuticals (warfarin) Kent Pharmaceuticals (aspirin, warfarin) Napp Pharmaceuticals (aspirin)

National Institute for Health and Clinical Excellence

Matrix for the appraisal of dabigatran etexilate for the prevention of stroke or systemic embolism in atrial fibrillation

Issue date: March 2010

Consultees Commentators (no right to submit or appeal) **British Cardiovascular Intervention** Pinewood Healthcare(aspirin) Society (BCIS) Reckitt Benckiser (aspirin) British Cardiovascular Society Sandoz (aspirin, warfarin) **British Geriatrics Society** Sigma Pharmaceuticals (aspirin) **British Heart Foundation** Sinclair Pharmaceuticals (aspirin) British Society for Haematology (BSH Teva UK (aspirin, warfarin) British Society for Haemostasis and Thornton & Ross (aspirin) Thrombosis (BSHT) Winthrop Pharmaceuticals (warfarin, British Society for Heart Failure aspirin) Clinical Leaders of Thrombosis Wockhardt UK (aspirin) (CLOT) Heart Rhythm UK Relevant research groups National Heart Forum (UK) British Society for Cardiovascular Research [BCS affiliated] Primary Care Cardiovascular Society Royal College of General Practitioners Cardiovascular Diseases Specialist Library (CVDSL) Royal College of Nursing • Central Cardiac Audit Database Royal College of Pathologists Cochrane Heart Group Royal College of Physicians Cochrane Peripheral Vascular Diseases Cardiology Committee Group Royal Pharmaceutical Society Royal Society of Medicine -Cochrane Stroke Group Intellectual Disabilities Forum CORDA MRC Clinical Trials Unit Society for Cardiological Science & Technology National Institute for Health Research United Kingdom Clinical Pharmacy Policy Research Institute on Ageing and Association **Ethnicity** Vascular Society Research Institute for the Care of Older People Others Wellcome Trust - Cardiovascular Department of Health Research Initiative NHS Richmond **Evidence Review Group** NHS Salford National Institute for Health Research Welsh Assembly Government Health Technology Assessment Programme West Midlands Health Technology Assessment Collaboration **Associated Guideline Groups** National Clinical Guidelines Centre Associated Public Health Groups None

National Institute for Health and Clinical Excellence Matrix for the appraisal of dabigatran etexilate for the prevention of stroke or systemic embolism in atrial fibrillation

Issue date: March 2010

Appendix B

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency and the *British National Formulary*.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.